Holly Sasser
Nurse Practitioner · Goldsboro, NCNPI 1538624267
Payments from drug & device makers
Across 137 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$492
- AbbVie$323
- Lilly USA, LLC$260
- Pfizer$149
- GSK$142
- Boehringer Ingelheim$139
- plus $839 from 20 others
What the payments were for
- Food & beverage$2,344100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $492 |
| AbbVie | 18 | $323 |
| Lilly USA, LLC | 15 | $260 |
| Pfizer | 10 | $149 |
| GSK | 10 | $142 |
| Boehringer Ingelheim | 7 | $139 |
| Abbott | 5 | $117 |
| AstraZeneca | 6 | $85 |
| Amgen | 4 | $62 |
| Johnson & Johnson | 3 | $59 |
| Exact Sciences | 3 | $56 |
| Astellas Pharma US Inc | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Merck | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$2,344 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 125 | $154,485 |
| OzempicSemaglutide | 69 | $109,116 |
| JardianceEmpagliflozin | 70 | $70,034 |
| FarxigaDapagliflozin Propanediol | 51 | $60,397 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $49,527 |
| EliquisApixaban | 42 | $43,475 |
| XareltoRivaroxaban | 55 | $32,211 |
| JanuviaSitagliptin Phosphate | 27 | $27,960 |
| RybelsusSemaglutide | 18 | $22,363 |
| LinzessLinaclotide | 16 | $20,199 |
| MyrbetriqMirabegron | 15 | $20,024 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $17,944 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $13,349 |
| Spiriva HandihalerTiotropium Bromide | 16 | $10,533 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 120 | $3,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $260 | $154,485125 claims |
| Novo NordiskOzempic, Rybelsus | $492 | $131,47987 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $142 | $80,821115 claims |
| Boehringer IngelheimJardiance | $139 | $70,03470 claims |
| AstraZenecaFarxiga | $85 | $60,39751 claims |
| PfizerEliquis | $149 | $43,47542 claims |
| Johnson & JohnsonXarelto | $59 | $32,21155 claims |
| MerckJanuvia | $50 | $27,96027 claims |
| AbbVieLinzess, Synthroid | $323 | $21,63830 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $20,02415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Goldsboro
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
- Deborah AllenDurham$112K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
- Mary DilorenzoCharlotte$71K
- Olivia OgburnWinston Salem$70K
- Bridget ArchambaultDurham$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.